Harpoon Therapeutics, Inc.
Harpoon Therapeutics, Inc. (HARP) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · HARP · as of Dec 31, 2023
Ownership Breakdown
1
Institutional Holders
▼ 1 vs Q3
$21.14M
Total Inst. Value
▲ $18.60M vs Q3
37.60M
Shares Outstanding
freeFloat 68.00%
1.86M
13F Shares Held
▲ 1.23M vs Q3
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
HARP largest shareholders · institutional ownership
Q4 2023 · SEC 13F
Showing top 2 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
NEW LEAF VENTURE PARTNERS, L.L.C. biological products, (no diagnostic substances) | 1.86M | 47.09% | 47.09% | $21.14B | Feb 14, 2024 | ▲ 1.54M |
MPM ASSET MANAGEMENT LLC biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Feb 13, 2024 | EXIT |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q4 2023 vs prior quarter
Q4 2023
1
Increased
+1.54M shares0
New Positions
first time holders0
Decreased
−0 shares1
Sold Out
fully exitedNet shares change (top 50)
+1.54M
+1.54M / −0
Net new holders
+0
0 new / 1 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
HARP insider trading · insider activity
Source: SEC Form 4
11
Buy transactions
41
Sell transactions
0.27
Buy/Sell ratio
$2M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
New Leaf Biopharma Opportunities II, L.P.
| Mar 11, 2024 | D-Return | 299,430 | $9.79 | $2.93M | 0 | Form 4 ↗ |
New Leaf Biopharma Opportunities II, L.P.
| Mar 11, 2024 | D-Return | 395,783 | $23.00 | $9.10M | 0 | Form 4 ↗ |
New Leaf Biopharma Opportunities II, L.P.
| Mar 11, 2024 | D-Return | 10,000 | $0.00 | $1 | 0 | Form 4 ↗ |
New Leaf Biopharma Opportunities II, L.P.
| Mar 11, 2024 | D-Return | 85,750 | $5.83 | $500.3K | 0 | Form 4 ↗ |
SILVERNAIL LAUREN P director | Mar 11, 2024 | D-Return | 5,000 | $23.00 | $115.0K | 0 | Form 4 ↗ |
SILVERNAIL LAUREN P director | Mar 11, 2024 | D-Return | 2,033 | $16.20 | $32.9K | 0 | Form 4 ↗ |
SILVERNAIL LAUREN P director | Mar 11, 2024 | D-Return | 2,300 | $6.66 | $15.3K | 0 | Form 4 ↗ |
HUNT RONALD
| Mar 8, 2024 | Award | 424 | — | — | 13.2K | Form 4 ↗ |
HUNT RONALD
| Mar 11, 2024 | D-Return | 10,000 | $0.00 | $1 | 0 | Form 4 ↗ |
HUNT RONALD
| Mar 11, 2024 | D-Return | 299,430 | $9.79 | $2.93M | 0 | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Harpoon Therapeutics, Inc. (HARP) is primarily owned by institutional investors, who hold approximately 5.0% of total shares outstanding. Company insiders own approximately 32.00%, while retail and public investors account for the remaining 63.05%.
The largest institutional shareholder of Harpoon Therapeutics, Inc. is NEW LEAF VENTURE PARTNERS, L.L.C., holding approximately 1.86 million shares — equal to 47.09% of outstanding shares — as of December 31, 2023.
A total of 1 institutional investors currently hold HARP stock, with a combined institutional value of approximately $21,138,740 as of the most recent 13F filing period.
Frequently asked questions
HARP ownershipHarpoon Therapeutics, Inc. (HARP) is primarily owned by institutional investors, who hold approximately 5.0% of shares. The largest shareholder is NEW LEAF VENTURE PARTNERS, L.L.C. with a 47.09% stake. Company insiders hold 32.00%. Data sourced from SEC Form 13F as of December 31, 2023.